Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Mar 25, 2024 9:57pm
110 Views
Post# 35952065

RE:RE:RE:RE:RE:RE:RE:Start of new week recap

RE:RE:RE:RE:RE:RE:RE:Start of new week recapSince the Phase 1b pancreatic cancer study involving Keytruda, which required ONCY to purchase Keytruda from Merck at full retail cost, ONCY went on to develop a supply agreement with Roche,  which was a normal agreement where both parties supplied each other's product, atezolizumab from Roche and pelareorep from ONCY at no cost, in pursuit of a common clinical trial goal, which began with the Phase 1/2 Goblet basket studies in multple cancer that includes pancreatic, anal, colorectal and GI cancers.

ONCY has come a long way from the first IND in pancreatic cancer in combination with any immune checkpoints inhibitor.
<< Previous
Bullboard Posts
Next >>